Health Canada clears Rybelsus for cardiovascular risk reduction

Health Canada has approved Rybelsus, an oral form of semaglutide, for a new use: reducing the risk of major cardiovascular events in adults with type 2 diabetes who already have cardiovascular disease or are at high risk for it. The move follows the US Food and Drug Administration's approval of the same indication for Rybelsus on October 17, 2025 ^[2].

Rybelsus was first approved by the FDA in September 2019 as a once-daily pill to help control blood sugar in adults with type 2 diabetes ^[2]. The newer indication expands its label to include reducing the risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke, collectively known as major adverse cardiovascular events, in patients at high risk for these outcomes ^[2].

There is a wrinkle in the Rybelsus name that matters for patients trying to track their prescriptions. The drug originally came in two formulations: an R1 version in 3 mg, 7 mg, and 14 mg tablets, and a newer R2 version in 1.5 mg, 4 mg, and 9 mg tablets that the FDA first approved in December 2024. On January 30, 2026, the FDA approved a labeling change that renamed the R2 formulation "Ozempic tablets." As a result, the Rybelsus name now applies only to the original R1 formulation, while the newer dose strengths are marketed as Ozempic tablets ^[2]. Health Canada's approval, as described, applies to Rybelsus; the sources reviewed do not specify whether Canadian regulators are treating the two formulations the same way as the FDA.

Rybelsus carries warnings for acute pancreatitis, complications of diabetic retinopathy, low blood sugar when combined with insulin or certain other diabetes drugs, kidney injury linked to fluid loss, severe gastrointestinal reactions, allergic reactions, and a risk of inhaling stomach contents during general anesthesia or deep sedation ^[2]. The most common side effects, each reported in at least 5% of patients in trials, are nausea, abdominal pain, diarrhea, decreased appetite, vomiting, and constipation ^[2].

Why it matters for patients

For Canadian patients with type 2 diabetes who also have cardiovascular disease or are at high risk for it, this approval means Rybelsus can now be prescribed specifically with heart attack and stroke prevention in mind, not just blood sugar control. That distinction can affect how a patient's care team frames the medication's goals and how insurers or public drug plans evaluate coverage requests tied to cardiovascular risk.

The rebranding of the newer Rybelsus dose strengths as Ozempic tablets in the US adds a layer of confusion that patients filling prescriptions across borders, or comparing US and Canadian drug information, should be aware of. The name on a pill bottle or pharmacy label may not match what a patient expects based on prior conversations with a doctor or previous prescriptions ^[2].

The broader market for semaglutide products, including Rybelsus, Ozempic, and Wegovy, was valued at $34.52 billion globally in 2025 and is projected to grow to $86.05 billion by 2034, with North America accounting for 69.09% of that market in 2025 ^[1]. Manufacturers have also moved to cut list prices for Wegovy, Ozempic, and Rybelsus in the US as part of efforts to expand access ^[1]. Neither of these market-level facts confirms specific pricing or availability details for Rybelsus in Canada under the new cardiovascular indication.

What happens next

The sources reviewed do not specify a timeline for when Canadian pharmacies will begin filling Rybelsus prescriptions under the new cardiovascular indication, nor do they detail how Canadian drug plans will handle coverage. In the US, the FDA's related decision to rename Rybelsus's newer dose strengths as Ozempic tablets took effect January 30, 2026, and that product was expected to become available in the US market during the second quarter of 2026 ^[2].